Consistent with these results, Ses treatment significantly decreased the hepatic IL-1β level (assessed by ELISA, Figure 3G) and activated caspase-1 level (assessed using fluorescence staining, Figure 3H) in NASH mice. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.